I would guess PFE gets some tax savings but I think PPS surge more likely do to anticipation of a blockbuster deal. Normally an acquiring company has a dip or stagnation with a big buyout but I think due to all the unique circumstances, even outside of tax reform, that a big deal will
propel PFE PPS. Management does not get enough credit for growth, as they have performed very well even after blockbusters like Lipitor and Viagra fell off patent. With big merger with BMY, as an example, they can get lots of synergies and growth with Eliquis and really expand oncology and biologics. it is much harder to penetrate an off patent biologic for a generic company because of pharmacy inventory issues and the marketing costs that a generic drug company would have to incur.
For instance, lets assume PFE and J&J have a cheaper biosimilar of a BMY biologic. First, the doctor would have to actually prescribe the PFE drug as they do not work like generic drugs. Second, if the Pharmacy only has the main brand and J&J in stock the pharmacy would auto fill the main BMY drug because of how the system works. If there are 4 knockoffs it becomes less likely that a pharmacy will stock all of them. that is simplified walkabout.
I keep guessing BMY as a takeout but whatever company it is I expect it to be the largest pharma buyout. Wouldn't be the first time.
Recent PFE News
- Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets • Business Wire • 09/25/2024 09:00:00 PM
- Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union • Business Wire • 09/20/2024 12:11:00 PM
- Targeting Cancer's Achilles Heel: AI-Driven DDR Therapies Offer Hope • AllPennyStocks.com • 09/17/2024 09:01:00 PM
- Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call with Analysts • Business Wire • 09/17/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 05:12:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 05:11:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 05:06:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 05:04:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 04:57:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 04:56:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 04:54:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 04:53:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 04:52:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 04:47:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 04:45:23 PM
- Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia • Business Wire • 09/14/2024 12:45:00 PM
- Pfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer • Business Wire • 09/14/2024 08:15:00 AM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 09/13/2024 08:49:43 PM
- Pfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024 • Business Wire • 09/11/2024 10:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 10:10:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 10:05:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 10:05:28 PM
- Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference • Business Wire • 08/28/2024 02:00:00 PM
- Pfizer Launches PfizerForAll™, a Digital Platform that Helps Simplify Access to Healthcare • Business Wire • 08/27/2024 10:45:00 AM
- Cruise and Uber Join Forces for Robotaxis, Alibaba Shifts Primary Listing to Hong Kong, Altria Hikes Dividend 4.1% • IH Market News • 08/23/2024 12:20:26 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM